IPVS STATEMENT on HPV vaccination: No longer supply constraints: Towards achieving WHO vaccine targets

Garland SM 1 , Bhatla N 2 , Woo YL 3 , IPVS Policy Committee

Affiliations 

  • 1 Reproductive & Neonatal Infectious Diseases, Department of Obstetrics and Gynaecology, University of Melbourne, Director Centre Women's Infectious Diseases Research, Honorary Research Fellow, Infection & Immunity, Murdoch Children's Research Institute, Parkville, VIC 3052, Australia. Electronic address: Suzanne.Garland@thewomens.org.au
  • 2 Department of Obstetrics & Gynaecology, Room 3101, Teaching Block, All India Institute of Medical Sciences, New Delhi 110029, India
  • 3 Department of Obstetric and Gynaecology, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, W.Persekutuan Kuala Lumpur, Malaysia. Electronic address: ylwoo@ummc.edu.my
Vaccine, 2024 Dec 02;42(26):126400.
PMID: 39366196 DOI: 10.1016/j.vaccine.2024.126400

Abstract

The global supply of human papillomavirus (HPV) prophylactic vaccines has been constrained since 2020.Vaccine manufacturers have increased capacity and new HPV vaccines are now available. Vaccine supply is now able to meet the full HPV vaccine demand which has been achieved earlier than predicted.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications